<DOC>
	<DOCNO>NCT00107952</DOCNO>
	<brief_summary>Study 0015 ( NCT00107952 ) compare safety effectiveness investigational drug , telavancin , vancomycin treatment hospital-acquired pneumonia .</brief_summary>
	<brief_title>Comparison Telavancin Vancomycin Hospital-acquired Pneumonia Due Methicillin-resistant Staphylococcus Aureus</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Staphylococcal Infections</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Methicillin</mesh_term>
	<mesh_term>Telavancin</mesh_term>
	<criteria>Clinical sign symptom consistent pneumonia acquire least 48 hour continuous stay inpatient acute chronic care facility acquire within 7 day discharge hospitalization great equal 3 day duration . Received 24 hour potentially effective systemic ( IV , IM PO ) antibiotic therapy Grampositive pneumonia immediately prior randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Nosocomial pneumonia</keyword>
	<keyword>MRSA</keyword>
</DOC>